Somerset Indus Capital Partners Fund III Success

Somerset Indus Capital Partners has declared the successful fundraising of its third fund, Fund III, which has reached $288 million, surpassing the initial target of $250 million. Fund III gained strong interest from a wide array of global institutional investors, including development finance institutions, international investment firms, local financial entities, insurance firms, funds of funds, family offices, and impact investors from Europe, the United States, and Southeast Asia.

Focus Areas of Fund III

With the establishment of Fund III, Somerset aims to focus on bridging healthcare access gaps within India’s “missing middle,” specifically within Tier II and Tier III markets. The fund intends to invest in scalable healthcare enterprises that provide affordable and accessible quality care in sectors such as healthcare delivery, pharmaceuticals, medical devices, diagnostics, and related fields.

Investment Strategy

Somerset generally invests between $15 million and $40 million in each portfolio company. However, through co-investment syndication with its LP network, the firm has the ability to engage in much larger transactions, ranging from $60 million to $80 million.

The influx of capital will allow Somerset to pursue larger and more structurally transformative opportunities in various domains such as preventive care and OPD-linked insurance, healthcare financing, embedded insurance solutions, value-driven generics, India-focused MedTech innovations, and diagnostics platforms aimed at enhancing accessibility and standardisation beyond metropolitan areas.

Early Investments from Fund III

To date, Fund III has already made three investments, which include Cyrix Healthcare, Printmann Offset, and NU Hospitals. Somerset reports that its previous funds have performed impressively, with Fund I achieving approximately 4.0x DPI. Fund II is progressing towards exits, having completed its first realisation in September 2025 at around 4x MOIC.